Collection
New developments in delivery technology, materials, and molecular engineering for drug discovery
This Journal of Hematology & Oncology series covers new technology, materials, and models for drug discovery. Development and applications of organoids, 3D cultures, PDX modes, nano-molecules, AI technology, and single-cell maps for drug discovery will be the focus.
Articles published in the collection have already gone through the systematic peer review process of the journal.
Articles (20 in this collection)
-
-
Optical nanomaterial-based detection of biomarkers in liquid biopsy
Authors (first, second and last of 4)
-
Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned
Authors (first, second and last of 11)
-
Reactive oxygen species (ROS) scavenging biomaterials for anti-inflammatory diseases: from mechanism to therapy
Authors (first, second and last of 6)
-
Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression
Authors (first, second and last of 13)
-
Direct inhibition of dioxygenases TET1 by the rheumatoid arthritis drug auranofin selectively induces cancer cell death in T-ALL
Authors (first, second and last of 11)
-
-
CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer
Authors (first, second and last of 10)
-
Advances in single-cell RNA sequencing and its applications in cancer research
Authors (first, second and last of 12)
-
-
-
Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies
Authors (first, second and last of 10)
-
Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells
Authors (first, second and last of 9)
-
-
Electrostatic anti-CD33-antibody–protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia
Authors (first, second and last of 27)
-
SIRPα-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47/SIRPα signal pathway via blocking the “don’t eat me” signal and activating the “eat me” signal
Authors (first, second and last of 17)
-
Matched related transplantation versus immunosuppressive therapy plus eltrombopag for first-line treatment of severe aplastic anemia: a multicenter, prospective study
Authors (first, second and last of 12)
-
NBAS, a gene involved in cytotoxic degranulation, is recurrently mutated in pediatric hemophagocytic lymphohistiocytosis
Authors (first, second and last of 17)
-
Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy
Authors (first, second and last of 10)
-
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
Authors (first, second and last of 13)
